Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination in lung cancer patients receiving immune checkpoint inhibitors: A multicenter observational study in Japa
Not Applicable
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000044316
- Lead Sponsor
- Shonan Fujisawa Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they were in the following condition; (1) having already received the vaccine; (2) not wishing to be vaccinated by their own choice or on the recommendation of their physician; and (3) did not provide informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method